Helix BioPharma Announces Q2 2009 Financi...( AURORA Ontario March 16 /- Helix BioP...)

AURORA, Ontario, March 16 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second quarter of fiscal 2009, ended January 31, 2009.

RECENT HIGHLIGHTS

• Helix filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission which became effective on March 12, 2009

• Helix received regulatory approval to commence a small European Phase II pharmacokinetic study in human subjects prior to initiating its planned Phase IIb/III trials

• Dr. Chao presented L-DOS47's mechanism of action at the Second Conference of Lung Cancer in Warsaw, Poland.

Results from Operations

Three and six month periods ended January 31, 2009 compared to the same periods in the previous year

Loss for the period

The Company recorded a loss of $4,252,000 and $6,573,000, respectively, for the three and six month periods ended January 31, 2009, for a loss per common share of $0.08 and $0.13, respectively. In the comparative three and six month periods ended January 31, 2008, the Company recorded a loss of $1,526,000 and $3,170,000, respectively, for a loss per common share of $0.04 and $0.08, respectively.

Revenues

Total revenues for the three month period ended January 31, 2009 totaled $863,000 (2008 - $791,000), resulting in an increase of $72,000 or 9.1%. Total revenues, for the six month period ended January 31, 2009 totaled $1,982,000 (2008 - $1,676,000), resulting in an increase of $306,000 or 18.3%.

Product Revenue

Product revenue totaled $740,000 and $1,661,000 respectively for the three and six month periods ended January 31, 2009 and represent an increase of $88,000 (13.5%
'/>"/>